FBRX News & Events

The deal size was increased to $150M and priced at the closing price. Guggenheim is acting as sole book running manager for the offering.

Forte Biosciences announced that it has commenced an underwritten public offering of shares of its common stock. Guggenheim Securities is acting as book-running manager for the offering.

"The clinical development for FB102 continues to progress well with important readouts in 2026," said Forte Biosciences CEO Paul Wagner, PhD. "The topline results from our phase 2 celiac disease study is expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is expected to have topline results in 1H 2026 and the alopecia areata phase 1b data readout is expected in 2026. This will be a very eventful year and further highlight FB102's potential to address the significant unmet medical needs across multiple indications representing multi-billion dollar potential market opportunities."